No Data
No Data
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
SAN DIEGO, May 30, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to
Cidara Therapeutics Inc. Hits Snag: Delayed 10-K Filing Complicates Capital Raising Efforts
Express News | Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Buy Rating Justified by Cidara Therapeutics' Upcoming Clinical Trials and Expanding Oncology Pipeline
Cidara Therapeutics | 10-Q: Quarterly report
Cidara Therapeutics: Closed a $240M Private Placement Led by RA Cap Management >CDTX
Cidara Therapeutics: Closed a $240M Private Placement Led by RA Cap Management >CDTX
No Data